279 related articles for article (PubMed ID: 21980429)
1. Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer.
Schütz SV; Schrader AJ; Zengerling F; Genze F; Cronauer MV; Schrader M
PLoS One; 2011; 6(9):e25341. PubMed ID: 21980429
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of glycogen synthase kinase-3beta promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines.
Schütz SV; Cronauer MV; Rinnab L
J Cell Biochem; 2010 Apr; 109(6):1192-200. PubMed ID: 20127713
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer.
Liao X; Thrasher JB; Holzbeierlein J; Stanley S; Li B
Endocrinology; 2004 Jun; 145(6):2941-9. PubMed ID: 14988390
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful?
Rinnab L; Schütz SV; Diesch J; Schmid E; Küfer R; Hautmann RE; Spindler KD; Cronauer MV
Neoplasia; 2008 Jun; 10(6):624-34. PubMed ID: 18516299
[TBL] [Abstract][Full Text] [Related]
5. Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations.
Rivest P; Renaud M; Sanderson JT
Chem Biol Interact; 2011 Feb; 189(3):177-85. PubMed ID: 21111724
[TBL] [Abstract][Full Text] [Related]
6. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells.
Li Y; Wang Z; Kong D; Li R; Sarkar SH; Sarkar FH
J Biol Chem; 2008 Oct; 283(41):27707-27716. PubMed ID: 18687691
[TBL] [Abstract][Full Text] [Related]
7. Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells.
Li Y; Wang Z; Kong D; Murthy S; Dou QP; Sheng S; Reddy GP; Sarkar FH
J Biol Chem; 2007 Jul; 282(29):21542-50. PubMed ID: 17522055
[TBL] [Abstract][Full Text] [Related]
8. Lenticular mitoprotection. Part B: GSK-3β and regulation of mitochondrial permeability transition for lens epithelial cells in atmospheric oxygen.
Brooks MM; Neelam S; Cammarata PR
Mol Vis; 2013; 19():2451-67. PubMed ID: 24319338
[TBL] [Abstract][Full Text] [Related]
9. A screen for transcription factor targets of glycogen synthase kinase-3 highlights an inverse correlation of NFκB and androgen receptor signaling in prostate cancer.
Campa VM; Baltziskueta E; Bengoa-Vergniory N; Gorroño-Etxebarria I; Wesołowski R; Waxman J; Kypta RM
Oncotarget; 2014 Sep; 5(18):8173-87. PubMed ID: 25327559
[TBL] [Abstract][Full Text] [Related]
10. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer.
Liao X; Zhang L; Thrasher JB; Du J; Li B
Mol Cancer Ther; 2003 Nov; 2(11):1215-22. PubMed ID: 14617795
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of GSK-3beta ameliorates hepatic ischemia-reperfusion injury through GSK-3beta/beta-catenin signaling pathway in mice.
Xia YX; Lu L; Wu ZS; Pu LY; Sun BC; Wang XH
Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):278-84. PubMed ID: 22672822
[TBL] [Abstract][Full Text] [Related]
12. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
Gravina GL; Marampon F; Muzi P; Mancini A; Piccolella M; Negri-Cesi P; Motta M; Lenzi A; Di Cesare E; Tombolini V; Jannini EA; Festuccia C
Endocr Relat Cancer; 2013 Jun; 20(3):321-37. PubMed ID: 23507703
[TBL] [Abstract][Full Text] [Related]
13. Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFκB via suppression of GSK-3β expression.
Ban JO; Oh JH; Son SM; Won D; Song HS; Han SB; Moon DC; Kang KW; Song MJ; Hong JT
Cancer Biol Ther; 2011 Aug; 12(4):288-96. PubMed ID: 21613824
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
Kunnimalaiyaan M; Vaccaro AM; Ndiaye MA; Chen H
Mol Cancer Ther; 2007 Mar; 6(3):1151-8. PubMed ID: 17363508
[TBL] [Abstract][Full Text] [Related]
15. Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway.
Liu S; Vinall RL; Tepper C; Shi XB; Xue LR; Ma AH; Wang LY; Fitzgerald LD; Wu Z; Gandour-Edwards R; deVere White RW; Kung HJ
Oncogene; 2008 Jan; 27(4):499-505. PubMed ID: 17653089
[TBL] [Abstract][Full Text] [Related]
16. Lenticular mitoprotection. Part A: Monitoring mitochondrial depolarization with JC-1 and artifactual fluorescence by the glycogen synthase kinase-3β inhibitor, SB216763.
Brooks MM; Neelam S; Fudala R; Gryczynski I; Cammarata PR
Mol Vis; 2013; 19():1406-12. PubMed ID: 23825920
[TBL] [Abstract][Full Text] [Related]
17. GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma.
Dal Col J; Dolcetti R
Cell Cycle; 2008 Sep; 7(18):2813-6. PubMed ID: 18769147
[TBL] [Abstract][Full Text] [Related]
18. 6BIO Enhances Oligonucleotide Activity in Cells: A Potential Combinatorial Anti-androgen Receptor Therapy in Prostate Cancer Cells.
Zhang X; Castanotto D; Nam S; Horne D; Stein C
Mol Ther; 2017 Jan; 25(1):79-91. PubMed ID: 28129131
[TBL] [Abstract][Full Text] [Related]
19. Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer.
Darrington RS; Campa VM; Walker MM; Bengoa-Vergniory N; Gorrono-Etxebarria I; Uysal-Onganer P; Kawano Y; Waxman J; Kypta RM
Int J Cancer; 2012 Sep; 131(6):E872-83. PubMed ID: 22539113
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth.
Mazor M; Kawano Y; Zhu H; Waxman J; Kypta RM
Oncogene; 2004 Oct; 23(47):7882-92. PubMed ID: 15361837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
